Custom Search

Register
Sign In
Sign In Using Facebook

US FDA ‘Satisfied’ With Indian Pharma’s Manufacturing Facility

by Gopalan on  January 21, 2010 at 11:50 AM Corporate News
  •   Print
  •   Share
  •   Comments
  •  Text 
 US FDA ‘Satisfied’ With Indian Pharma’s Manufacturing Facility
Indian pharma major Lupin says the US FDA is now satisfied with the corrective actions taken at its Mandideep facility in Madhya Pradesh. An official communication has been received from the US agency on the issue.


In May last year, the FDA had warned the company that no new product would be approved until it took corrective action to address the deficiencies in the Mandideep manufacturing plant. It is Lupin’s only plant manufacturing cephalosporins, which contribute about 45% of its total revenue.

The FDA inspection found several deficiencies in the Good Manufacturing Standards (GMP) standards set by the agency and issued Inspectional Observations also known as Form 483 listing all the deviations.

It cited Lupin’s failure to maintain production, control, or distribution records and failure to follow appropriate written procedures designed to prevent microbiological contamination of drug products to be sterile.

Lupin’s Mandideep facility was also found to be lacking in controls to prevent contamination in defined areas regarding operations related to aseptic processing of products. The plant managers also failed to routinely calibrate, inspect, or check according to a written programme designed to assure proper performance of automatic, mechanical, or electronic systems.

“The USFDA issued a warning letter for the cephalosporin (antibiotic compounds) facility of the Mandideep plant (in Madhya Pradesh). The facility was inspected in November 2008 for a routine GMP (good manufacturing practices) inspection. As a result, Lupin had received 15 procedural observations,” Lupin sated in a press release while announcing its fourth quarter results for the period 2008-09.

Page 1 Page 1 | 2  Next
 Email Email   RSS Feeds RSS Feeds   Print this page Print   Save this page Save   Link Link   Syndicate Syndicate   Comments Comments   Bookmark and Share
 
Comment & Contribute
Be the first to comment!
Comments should be on the topic and should not be abusive. Comments are normally moderated and are reviewed after they are posted.
* Your comment can be maximum of 2500 characters

Notify me when reply is posted
I agree to the terms and conditions
  

X

Medwonders Health Network

  • Health News Index
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Archive
Date :
Category :
Keyword :
  • News Quick Links
News Central Health Watch
Latest Health News Health In Focus
News Category (500+) Breaking Health News
Popular News Celebrating Life
Health News and Press Release Medindia - Exclusive
News Photo Gallery India Special
News Video Gallery Lifestyle and Wellness
News From Other Resources
News Categories:  
Obesity Health Center

Corporate Related News

» Pfizer Initiates Recall of Birth Control Pills in the US » J&J Initiates Voluntary Recall of Aveeno Baby Lotion
» Fortis to Launch Chain of Dialysis Centers to Broaden Access to Quality Care » Pacific Edge Buoyed by European Acceptance of Gastric Cancer Detection Patents
» FDA Approves Abbott’s Xience Prime Coronary Stent » Circadian Technologies’ Investigative Cancer Drug Receives FDA Nod for Clinical Trials
» CooperVision Issues Another Statement Over Contact Lens Recall » Conditional Nod for Proposed Teva Buy
Read More >>